Journal article
Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate
S Svobodová, J Browning, D MacGregor, G Pollara, RA Scolyer, R Murali, JF Thompson, S Deb, A Azad, ID Davis, JS Cebon
European Journal of Cancer | Published : 2011
Abstract
To determine the effect of Cancer-Testis Antigen (CTAg) expression on the natural history of primary cutaneous melanoma we compared its impact on prognosis with that of known prognostic factors and its relationship with other clinicopathologic characteristics. The immunohistochemical expression of three CTAgs (MAGE-A1, MAGE-A4 and NY-ESO-1) in 348 cases of stage I and stage II primary cutaneous melanoma was analysed and correlated with clinicopathologic characteristics, relapse free survival (RFS) and overall survival (OS). A Cox proportional hazards regression model was used to analyse factors which independently predicted RFS. All three CTAgs were significantly co-expressed with each other..
View full abstractGrants
Funding Acknowledgements
[ "This work was conducted as part of the Hilton-Ludwig Cancer Metastasis Initiative, funded by the Conrad N. Hilton Foundation and the Ludwig Insitute for Cancer Research.", "The following Austin Health medical oncology fellows contributed patient tumours to this study: Mark Shackleton, Phillip Parente, Catherine Barrow and Oliver Klein. We also thank Sunanta Lee and Belinda Rutledge who created and maintain the melanoma database. I.D.D. is supported in part by a Victorian Cancer Agency Clinical Researcher Fellowship and is an Australian National Health and Medical Research Council (NHMRC) Honorary Practitioner Fellow. J.C. is an NHMRC Practitioner Fellow. R.A.S. and R.M. are supported by the Cancer Institute New South Wales Clinical Research Fellowship program. Assistance of the staff of the Melanoma Institute Australia/Sydney Melanoma Unit is also gratefully acknowledged." ]